Portuguese point-of-care diagnostics company biosurfit has gained CE-mark approval for its HbA1c clinical blood test to assist doctors diagnose diabetes. The three-in-one haematology/immunoassays/clinical chemistry test is designed to identify patients who may be at risk for developing diabetes.
HbA1c tests are one of the most common diagnostic tools to diagnose diabetes, and biosurfit's test is designed to make...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?